The Tecan Group announced the acquisition of US-based SPEware Corporation (SPEware) to further expand Tecan's dedicated solutions offering into a new market segment. SPEware is a leading provider for mass spectrometry sample preparation solutions, with a focus on the North American market. ... more
Tecan and Enigma Diagnostics sign global manufacturing and supply agreement for point-of-care Molecular Diagnostics instruments
The Tecan Group and Enigma Diagnostics Limited announced the signing of a manufacturing and supply agreement for Enigma's ML instruments. Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma's global market supplies for an initial five-year contract and will also manage the ML instrument's supply chain. Financial details of the agreement were not disclosed.
John McKinley, Chairman and CEO of Enigma, said: "This is a milestone agreement for Enigma. We chose Tecan for its leading reputation as a developer and manufacturer of commercial medical instruments and its global range of technical and support services network. This represents the first of a number of potential additional agreements relating to Tecan's support of the Enigma ML system."
- Enigma Diagnostics
- molecular diagnostics
Tecan announced the results of the Tecan Award 2011. The award has been won by Svenja Kristina Holle from the University Hospital of Muenster (UHM), Germany. Using an Infinite® 200 microplate reader, Svenja and the UHM team have developed an ex vivo method for investigating the dynamics of ... more
The Tecan Group announced that Martin Brusdeilins will take over as Head of the Development & Operations Division with immediate effect. Jürg Dübendorfer, who has led the Division since January 2011, is to leave the company and the Group Management Board at his own request by no later than ... more
The Tecan Group and Enigma Diagnostics Limited announced the signing of a manufacturing and supply agreement for Enigma's ML instruments. Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma's global market supplies for an initial fiv ... more
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced four senior appointments for its US and European offices. Dr. Jorge Garces will lead the US team as President and CEO with Greg Hamilton, Chief Operating Officer and Chief Financial Off ... more
Enigma Diagnostics Limited announced that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS). The licenses signed on15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemis ... more